CORE B: High-throughput Genomic and RNA Analysis

贝勒医学院的高通量基因组和RNA分析(HGRA)核心 (BCM)智力和发育障碍研究中心(IDDRC)利用资源 和BCM的微阵列核心设施(MCF)的知识库。这个新命名的核心 代表两个先前资助的IDDRC核心的组合(核心B2：基因组阵列核心 和核心C4：表达式数组核心)。作为一项新的活动，CORE还将提供下一代 向用户提供测序技术。基因组阵列核心最初是为了提供阵列 BCM-IDDRC使用者的比较基因组杂交(ACGH)。从那时起，BCM 医学遗传学实验室(CLIA认证的实验室环境)开发了一种靶向aCGH 该平台被称为染色体微阵列分析(CMA)。2006年，丽莎·D·怀特博士 成为CLIA CMA实验室的技术总监，许多BCM-IDDRC的研究人员开始 利用那个实验室进行aCGH。向CLIA实验室的转换取得了惊人的成功， 对IDD社区有巨大的好处，从列出的大量出版物中就可以看出 下面。这些努力已经导致了大量新的IDD基因病因。这个 HGRA将继续将aCGH作为BCM-IDDRC成员的研究活动作为 作为临床工作的补充。 HGRA核心将结合尖端技术，提供最先进的质量 基于微阵列和基于下一代测序的服务和分析 转录和基因组图谱。MCF成立于1999年，资金来自BCM， 国家癌症研究所和国家眼科研究所为BCM开发微阵列资源 研究人员。随着HGRA核心的重组，我们的目标扩展到提供 协助BCM-IDDRC研究人员利用下一代微阵列技术 测序技术，良好的实验设计，数据管理和数据分析 资源。我们将开始提供下一代测序技术(Illumina Genome 分析器II)于2009年3月提交给BCM-IDDRC成员。

The High-throughput Genomic and RNA Analysis (HGRA) Core for the Baylor College of Medicine (BCM) Intellectual and Developmental Disabilities Research Center (IDDRC) utilizes the resources and knowledge base of the Microarray Core Facility (MCF) at BCM. This newly named core represents a combination of two previously funded IDDRC cores (Core B2: Genomic Array Core and Core C4: Expression Array Core). As a new activity, the core will also offer next generation sequencing technology to users. Originally the Genomic Array Core was set up to offer array comparative genomic hybridization (aCGH) to users of the BCM-IDDRC. Since that time the BCM Medical Genetics Laboratories (a CLIA certified lab environment) developed a targeted aCGH platform which is called Chromosomal Microarray Analysis (CMA). In 2006, Dr. Lisa D. White became Technical Director of the CLIA CMA lab and many of the BCM-IDDRC researchers began using that laboratory for their aCGH. The switch to the CLIA lab has been stunningly successful and of immense benefit to the IDD community as illustrated by the large numbers of publications listed below. A very large number of new genetic etiologies for IDD have resulted from these efforts. The HGRA will continue to offer aCGH as a research activity for members of the BCM-IDDRC as an adjunct to the clinical efforts. The HGRA core will combine cutting edge technologies to provide state-of-the-art quality microarray-based and next generation sequencing-based services and analyses for both transcriptional and genomic profiling. The MCF was established in 1999 with funds from BCM, the National Cancer Institute and the National Eye Institute to develop microarray resources for BCM researchers. With the restructuring of the HGRA core, our purpose expands to providing assistance to BCM-IDDRC researchers in utilizing microarray technology, next generation sequencing technology, good experimental design, and data management and data analysis resources. We will begin offering next generation sequencing technology (Illumina Genome Analyzer II) to BCM-IDDRC members in March 2009.